GPS News  
INTERN DAILY
High Dose Of Oxygen Enhances Natural Cancer Treatment

A Petri dish with human cancer cells was placed in this high-pressure oxygen chamber for 48 hours. Source: Reimers Systems
by Hannah Hickey
Seattle, Washington (SPX) Apr 5, 2011
A technique Michael Jackson reportedly used to prolong his youth is showing promise as a way to boost the effectiveness of a natural cancer remedy. An environment of pure oxygen at three-and-a-half times normal air pressure adds significantly to the effectiveness of a natural compound already shown to kill cancerous cells, researchers at the University of Washington and Washington State University recently reported in the journal Anticancer Research.

The compound artemisinin - isolated from Artemisia annua L, commonly known as wormwood - is a natural remedy widely used to treat malaria. In the mid-1990s UW researchers were the first to explore its ability to treat cancer.

In the new study, using artemisinin or high-pressure oxygen alone on a culture of human leukemia cells reduced the cancer cells' growth by 15 percent. Using them in combination reduced the cells' growth by 38 percent, a 50 percent increase in artemisinin's effectiveness.

"If you combine high-pressure oxygen with artemisinin you can get a much better curing effect," said author Henry Lai, a UW research professor of bioengineering. "We only measured up to 48 hours. Over longer time periods we expect the synergistic effects to be even more dramatic."

The history of artemisinin brings to mind an Indiana Jones story. In the early 1970s, Lai says, Chinese leader Mao Zedong issued an order to develop an anti-malarial treatment. At the same time, a farmer in central China discovered a 2,000-year-old tomb that contained three coffins.

One coffin contained a silk scroll describing various prescriptions, including artemisinin to treat malaria. The Chinese followed the directions and thus rediscovered an ancient remedy.

Today, artemisinin is widely used in Asia and Africa for malaria treatment.

In the decades since, scientists have discovered artemisinin reacts with iron within a cell to form a free radical, a highly reactive charged particle that destroys the cell. Because the malaria parasite is high in iron, artemisinin targets malaria-infected cells.

Since rapidly dividing cancer cells also need iron to form new DNA, Lai theorized they would also make targets for artemisinin. Subsequent research showed this to be the case.

Lai and colleagues at the UW developed a variant several thousand times more potent than natural artemisinin, which was licensed in 2004 to a Chinese company.

"Artemisinin is a promising low-cost cancer treatment because it's specific, it's cheap and you don't have to inject it," Lai said. "It's 100 times more specific than traditional chemotherapy," he added. "In breast cancer, it's even better."

Lai says he's long hypothesized that high oxygen levels would enhance artemisinin's effects, because oxygen promotes the formation of free radicals. In 2010, he put the theory to the test in a hyperbaric chamber that co-author Raymond Quock, WSU professor and chair of pharmaceutical sciences, has been using to study highly pressurized oxygen's ability to relieve pain.

Hyperbaric chambers, filled with oxygen at high pressure, help scuba divers who surface too quickly gradually readjust to normal oxygen levels. A photo of pop singer Jackson in the mid-80s sleeping in a portable hyperbaric chamber sparked rumors that he was trying to heal scars from plastic surgery, retain his youthful appearance or extend his lifespan.

The photo turned out to be a publicity stunt, but the U.S. Food and Drug Administration has approved hyperbaric oxygen therapy for several ailments, including decompression sickness, carbon-monoxide poisoning, severe burns and slow-to-heal wounds.

In clinical practice, the artemisinin-hyperbaric study could lead to people or animals spending time in a hyperbaric chamber to enhance the artemisinin's effectiveness.

Other co-authors are Yusuke Ohgami, Catherine Elstad and Eunhee Chung of WSU and Donald Shirachi of the Chico Hyperbaric Center. The research was funded by the Washington State University College of Pharmacy and the Chico Hyperbaric Center.

In related artemisinin work, funded through a $1.5 million grant from the state's Life Sciences Discovery Fund to a team led by UW chemistry professor Tomikazu Sasaki:

UW researchers are developing synthetic artemisinin compounds with enhanced potency and anti-cancer selectivity, and WSU researchers are conducting a clinical trial evaluating these compounds' ability to treat cancer in dogs. The molecular-engineered artemisinin compounds, which are stronger and more targeted than natural artemisinin but can still be taken by mouth, are licensed to Artemisia Biomedical of Newcastle, Wash.

WSU crop scientists are planting Artemisia annua in eastern Washington to test whether the region could plant artemisinin as a commercial crop.

Researchers are working with Northwest Organic Foods, a Washington chicken-feed company, to try adding artemisinin, instead of small amounts of arsenic, to chicken feed. Artemisinin acts as a natural preventative for avian coccidia infection, one of the poultry industry's most costly parasitic diseases.



Share This Article With Planet Earth
del.icio.usdel.icio.us DiggDigg RedditReddit
YahooMyWebYahooMyWeb GoogleGoogle FacebookFacebook



Related Links
University of Washington
Hospital and Medical News at InternDaily.com



Memory Foam Mattress Review
Newsletters :: SpaceDaily :: SpaceWar :: TerraDaily :: Energy Daily
XML Feeds :: Space News :: Earth News :: War News :: Solar Energy News


INTERN DAILY
Patients Are Willing To Undergo Multiple Tests For New Cancer Treatments
Scottsdale AZ (SPX) Mar 07, 2011
Cancer patients are willing to undergo many tests to receive advanced experimental treatment in clinical trials, according to a new study by Mayo Clinic, Scottsdale Healthcare and the Translational Genomics Research Institute (TGen). Researchers said patients' willingness to undergo tests bodes well for the future of personalized medicine, in which specific treatments are prescribed depend ... read more







INTERN DAILY
Research On Satellite Imagery Aims To Advance Sustainable Agriculture

First ban on all Japanese food over nuclear crisis

Researchers Say Children Need Horticultural Interventions

New Information Provides Sustainable Options For Greenhouse Operations

INTERN DAILY
Smarter Memory Device Holds Key To Greener Gadgets

Self-Cooling Observed In Graphene Electronics

Texas Instruments to buy National Semiconductor

Tiny 'On-Chip Detectors' Count Individual Photons

INTERN DAILY
Australia's Qantas to offload ageing Boeing 737s

EADS expands in Canada, eyes U.S. market

Raven Industries Manufactured Balloon Sets Records

US airlines cut Tokyo service

INTERN DAILY
Resource-Friendly Car Manufacturing

Mobile With Electricity

Toyota says some US shutdowns 'inevitable'

Natural gas for U.S. vehicles?

INTERN DAILY
Startup serves up bargains to online shoppers

China becoming the Pacific's 'banker': thinktank

China's Minmetals eyes bid for Australian miner

Japan disaster to cost Australia $2 bln in lost trade

INTERN DAILY
Mangroves Among The Most Carbon-Rich Forests In The Tropics

"Epidemiological" Study Demonstrates Climate Change Effects On Forests

Declining mangroves shield against global warming

Macedonia plants three million trees to revive forests

INTERN DAILY
NASA Airborne Radar Set To Image Hawaiian Volcano

Record Loss Of Ozone Over Arctic

Salt-Seeking Spacecraft Arrives At Launch Site

Global Hawks Mark Year Of Science Flights

INTERN DAILY
Health Effects Of Amines And Their Derivatives

New Method For Preparation Of High-Energy Carbon-Carbon Double Bonds

CO2 Pressure Dissipates In Underground Reservoirs

Berkeley Lab Scientists Control Light Scattering In Graphene


The content herein, unless otherwise known to be public domain, are Copyright 1995-2010 - SpaceDaily. AFP and UPI Wire Stories are copyright Agence France-Presse and United Press International. ESA Portal Reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. Advertising does not imply endorsement,agreement or approval of any opinions, statements or information provided by SpaceDaily on any Web page published or hosted by SpaceDaily. Privacy Statement